March 27, 2005 Last week, the Centient Biotech 200 gained 8 points, which is a .26% rise, to close at 3195.59. That was a positive divergence as the rest of the market was lower. Nasdaq lost .83% and the NYSE Composite was down by a full 2%. We look at the rise in Genentech, as Avastin profits from the downfall of a rival, favorable comments about NPS pharma, the paired move upwards for Nektar and Eyetech, plus positive news released after the close on Thursday for Ista and Millenium. More details...
